Also trades as: ONC.TO (TSX) · $vol 0M
ONCY NASDAQ
Oncolytics Biotech Inc.
1W: -8.8%
1M: -29.2%
3M: -29.2%
YTD: -36.7%
1Y: -56.1%
3Y: -72.1%
5Y: -71.0%
$0.63
-0.01 (-1.59%)
Weekly Expected Move ±7.4%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$63.3M
52W Range0.6221-1.42
Volume609,206
Avg Volume1,242,289
Beta1.15
Dividend—
Analyst Ratings
Company Info
CEOJared Kelly
Employees29
SectorHealthcare
IndustryBiotechnology
IPO Date2001-10-05
Websiteoncolyticsbiotech.com
4350 Executive Drive
San Diego, CA 92121
US
San Diego, CA 92121
US
14036707380
About Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Latest News
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| McAdory John Bearden | 500,000 | $0.97 | 2026-06-01 | |
| Glover Stephen C. | 0 | — | 2026-06-01 | |
| Kelly Jared | P-Purchase | 5,050 | $0.96 | 2026-03-12 |
| Parsons James T. | P-Purchase | 10,000 | $1.03 | 2026-03-11 |
| Kelly Jared | P-Purchase | 29,500 | $0.84 | 2026-02-12 |